Combined endocrine effects of LHRH agonist (Zoladex®) and tamoxifen (Nolvadex®) therapy in premenopausal women with breast cancer
Data up to Jan 2025
Total Citations Per Year
Abstract
References (11)
Assessment of response to therapy in advanced breast cancer.A project of the programme on clinical oncology of the International Union against Cancer, Geneva, Switzerland
1977 • 633 citations
Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist
1985 • 299 citations
EFFECT OF THE ANTI-OESTROGEN TAMOXIFEN ON PLASMA LEVELS OF LUTEINIZING HORMONE, FOLLICLE-STIMULATING HORMONE, PROLACTIN, OESTRADIOL AND PROGESTERONE IN NORMAL PRE-MENOPAUSAL WOMEN
1976 • 154 citations
Endocrine status of premenopausal node-positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen.
1988 • 120 citations
The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer
1986 • 118 citations
Recurrent breast cancer treated with the antioestrogen tamoxifen: correlation between hormonal changes and clinical course.
1977 • 94 citations
ASSESSMENT OF RESPONSE TO TREATMENT IN ADVANCED BREAST CANCER
1974 • 81 citations
Anti-tumor and endocrine effects of chronic LHRH agonist treatment (Buserelin) with or without tamoxifen in premenopausal metastatic breast cancer
1984 • 44 citations
Endocrinological and clinical aspects of LHRH action (ICI 118630) in hormone dependent breast cancer
1985 • 38 citations
Combined effects of Buserelin, estradiol and Tamoxifen on the growth of MCF-7 human breast cancer cells in vitro
1986 • 37 citations
Preliminary endocrinological evaluation of a sustained-release formulation of the LH-releasing hormone agonist d-Ser(But)6Azgly10LHRH in premenopausal women with advanced breast cancer
1986 • 24 citations